Healthcare ❯ Pharmaceuticals

Weight Loss Drugs

GLP-1 Drugs GLP-1 Medications Wegovy Semaglutide GLP-1 Agonists Ozempic GLP-1 Receptor Agonists Mounjaro Novo Nordisk Tirzepatide Zepbound Eli Lilly Market Trends Clinical Trials GLP-1 Treatments GLP-1 GLP-1s FDA Approvals Market Competition Tirzepatide vs. Semaglutide Comparison Effectiveness Studies Clinical Studies Cost Barriers GLP-1 Products Regulatory Issues Prescription Medications Regulation Approval and Availability Drug Safety Viking Therapeutics Challenges Amycretin Cost Reduction and Access Side Effects Incretin Drugs Diabetes Treatments Mental Health GLP Inhibitors Consumer Access Tirzepatide (Zepbound) Metsera Survodutide Market Availability Obesity Treatments Financial Barriers Petrelintide Insurance Coverage Drug Development Semaglutide and Tirzepatide

GLP-1 Drugs Reshape Obesity Care

High prices, patchy insurance, temporary policy fixes limit patient access to GLP-1 medicines.

Novo Nordisk Sues Lilly Over Weight‑Loss Ads as GLP‑1 Rivalry Intensifies

Eli Lilly Trades at a High Multiple as GLP‑1 Catalysts Loom

UCL Review Finds GLP‑1 Drugs Reduce Binge Eating Symptoms

Generics and Pills Expand Access to GLP‑1s, but Uptake and Coverage Remain Uneven

Lilly’s GLP‑1 Sales and PBM Coverage Fuel Record Quarter as Pipeline Logs Durable Wins

GSK Gains After Cramer Endorsement as Company Pushes Into Weight-Loss Drugs

Novo Nordisk Invests €432 Million to Expand Athlone Plant for Oral GLP-1 Tablets

Eli Lilly Jumps on GLP‑1 Momentum as 2026 Outlook Beats and Targets Rise

Novo Nordisk’s Oral Wegovy Debuts With Strong Prescriptions as BMO Stays Cautious

Three Charged in Targeted Robbery of $16,000 in GLP-1 Drugs at Bensalem Pharmacy

Eli Lilly’s GLP-1 Lead Faces New Pressure From Novo’s Weight-Loss Pill

Eli Lilly Shifts to Access-First Strategy on GLP-1 Strength

Eli Lilly Briefly Hits $1 Trillion as GLP-1 Boom Spurs Fresh Analyst Targets

Eli Lilly Becomes First Health Care Company Valued at $1 Trillion

Lancet Analysis: Semaglutide Cuts Major Heart Events Regardless of Weight Loss

Lilly’s Oral GLP-1 Pill Meets Phase 3 Goals, Shares Rebound

Novo Nordisk Freezes Hiring as Layoffs Loom in GLP-1 Retrenchment